Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Randomized, Double-Blind, Placebo-controlled Study of Platinum (Cisplatin or Carboplatin) Plus Etoposide With or Without Toripalimab as First Line Therapy in Patients With Extensive Stage Small Cell Lung Cancer

Next Previous
Trial Profile

A Phase III Randomized, Double-Blind, Placebo-controlled Study of Platinum (Cisplatin or Carboplatin) Plus Etoposide With or Without Toripalimab as First Line Therapy in Patients With Extensive Stage Small Cell Lung Cancer

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 21 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Toripalimab (Primary) ; Carboplatin; Cisplatin; Etoposide
  • Indications Small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms EXTENTORCH; JUPITER-08
  • Sponsors Shanghai Junshi Biosciences

Most Recent Events

  • 16 Jan 2025 Status changed from active, no longer recruiting to completed.
  • 18 Jun 2024 According to a Shanghai Junshi Biosciences media release, the National Medical Products Administration (NMPA) has approved the supplemental new drug application (sNDA) for toripalimab (product code: JS001) in combination with etoposide plus platinum for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC).
  • 27 Oct 2023 According to Junshi Biosciences media release, data from this study will be presented at the European Society of Oncologists (ESMO) Immuno-Oncology Congress 2023

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top